James Antal, Director at CLEVELAND BIOLABS INC (CBLI), bought 2,105 shares at $2.73 ($6K) on 2011-12-16, disclosed to the SEC on 2011-12-20.
Scheduled purchase ($6k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $2.73 | 200 | $546 | 9.3% |
| 2 | $2.76 | 100 | $276 | 4.7% |
| 3 | $2.79 | 1,040 | $3K | 49.5% |
| 4 | $2.80 | 765 | $2K | 36.5% |
| Total | $2.79 avg | 2,105 | $6K | 100% |
| Filing → |
| SIGA | SELL | 2019-06-07 | $171K | — | Filing → |
| CBLI | BUY | 2013-03-18 | $6K | — | Filing → |
| CBLI | BUY | 2012-09-25 | $6K | — | Filing → |